Welcome to our dedicated page for LivaNova PLC Ordinary Shares news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC Ordinary Shares stock.
LivaNova PLC (symbol: LIVN) is a global leader in medical technology, with nearly five decades of experience and an unwavering mission to enhance patient outcomes around the world. Headquartered in London, UK, LivaNova operates in more than 100 countries and employs approximately 3,000 professionals. The company is publicly traded on the NASDAQ stock exchange.
Specializing in advanced circulatory support, cardiopulmonary solutions, and neuromodulation therapies, LivaNova offers a diverse portfolio of products designed to tackle serious health conditions. Their offerings include surgical heart valves, heart-lung machines, oxygenation equipment, and devices for treating conditions like treatment-resistant epilepsy and depression.
LivaNova was formed through a merger between Cyberonics from the US and Sorin from Italy, combining their strengths to create a powerhouse in medical devices. The company has since streamlined its focus by divesting its cardiac rhythm management and heart valve businesses, allowing it to concentrate on its core strengths.
The company’s commitment to innovation is evident through its continuous development of breakthrough treatments and advanced technologies. By emphasizing both clinical and economic value, LivaNova aims to benefit patients, healthcare professionals, and healthcare systems alike. Approximately half of LivaNova’s revenues are generated from the US, with Europe contributing 21%, and the rest coming from other global markets.
LivaNova’s expertise and global presence make it a significant player in the medical technology sector, dedicated to creating products and therapies that transform lives every day.
LivaNova (LIVN) reported strong Q3 2024 results with revenue of $318.1 million, up 11.2% year-over-year. The company's Cardiopulmonary segment revenue increased 15.4% to $172.2 million, while Neuromodulation grew 8.8% to $139.9 million. U.S. GAAP diluted earnings per share reached $0.60, with adjusted EPS at $0.90. Based on strong performance, LivaNova raised its full-year 2024 guidance, now expecting revenue growth between 8.5% and 9.5% on a constant-currency basis, and adjusted EPS of $3.30-$3.40.
LivaNova PLC (Nasdaq: LIVN) has appointed Susan Podlogar to its Board of Directors, effective immediately. Podlogar, who will serve on the Compensation and Human Capital Management Committee, brings 30 years of experience in leading business, talent, and cultural transformations at global companies. Her most recent role was Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 to June 2024. Prior to that, she spent 16 years at Johnson & Johnson in various leadership positions. Podlogar holds an MBA from the University of South Florida and a bachelor's degree from the University of Wisconsin-Parkside.
William Kozy, Chair of the Board, praised Podlogar's visionary leadership and understanding of the global business landscape. With this appointment, the LivaNova Board now consists of 10 Directors.
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced it will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The company will release its Q3 2024 results before the call. Investors and interested parties can access a live audiocast of the call at www.livanova.com/events.
To join the conference call by telephone, participants can dial +1 833 470 1428 from within the U.S. or +1 929 526 1599 from outside the U.S. The access code for the call is 881946. A replay of the call will be available on the LivaNova website for 90 days following the event.
LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, has announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation is scheduled for Tuesday, September 10, at 10:15 a.m. Eastern Time.
Interested parties can access the webcast through www.livanova.com/events. Attendees are advised to log on about 10 minutes early to ensure proper setup. A replay of the presentation will be available on the LivaNova website within 24 hours and will remain accessible for 90 days following the event.
LivaNova PLC (Nasdaq: LIVN) reported strong Q2 2024 results, with revenue increasing 8.4% to $318.6 million. Excluding the Advanced Circulatory Support segment wind down, revenue grew 10.8% on a constant-currency basis. U.S. GAAP diluted EPS was $0.30, while adjusted diluted EPS reached $0.93.
The Cardiopulmonary segment saw a 14.5% constant-currency growth, driven by EssenzTM Perfusion System sales. Neuromodulation revenue increased 7.8% on a constant-currency basis. LivaNova raised its full-year 2024 guidance, now expecting revenue growth between 7% and 8% on a constant-currency basis. Adjusted diluted EPS for 2024 is projected to be in the range of $3.10 to $3.20.
LivaNova (Nasdaq: LIVN), a leading medical technology company, will announce its second-quarter 2024 results on July 31, 2024. The results will be discussed in a conference call at 1 p.m. London time (8 a.m. Eastern Time). The event will be audiocast live on the company's website, www.livanova.com/events. Participants are advised to log on 10 minutes early for proper setup. The call can also be accessed via telephone using the provided numbers and access code 926038. A replay will be available on the company’s website for 90 days post-call.
LivaNova announced preliminary results for the unipolar patient cohort in its RECOVER clinical study of VNS Therapy for treatment-resistant depression. The primary endpoint (PE) did not achieve statistical significance due to an unforeseen strong response in the sham group. However, select secondary endpoints showed statistically significant and clinically meaningful benefits, with no safety concerns reported. The company plans to publish detailed data in peer-reviewed journals by Q4 2024. The RECOVER study's bipolar patient cohort continues, and discussions with U.S. Medicare and Medicaid Services for VNS Therapy coverage are ongoing.
LivaNova (Nasdaq: LIVN), a leading medical technology company, announced that its CEO, Vladimir Makatsaria, will participate in a fireside chat at the Goldman Sachs Healthcare Conference.
The event will take place in Miami, Florida, on June 10 at 1:20 p.m. Eastern Time. A webcast will be available for those who register on the LivaNova website.
The webcast will also be accessible as a replay for 90 days following the live presentation.
LivaNova PLC (Nasdaq: LIVN) reported strong first-quarter 2024 results with revenue of $294.9 million, a 12.0% increase, and adjusted diluted earnings per share of $0.73. The company raised its full-year 2024 revenue guidance to grow between 6-7% on a constant-currency basis. LivaNova achieved positive trial outcomes in the OSPREY clinical study for obstructive sleep apnea. The company closed a private offering of $345.0 million convertible senior notes due 2029 and repurchased $230.0 million exchangeable senior notes due 2025.
LivaNova PLC announced the appointment of Ahmet Tezel, Ph.D., as Chief Innovation Officer, effective May 13, 2024. Tezel will lead the development of new technologies leveraging his 20+ years of experience in research and development. His role will enhance the Company's innovation capabilities in neurological and cardiac health.
FAQ
What is the current stock price of LivaNova PLC Ordinary Shares (LIVN)?
What is the market cap of LivaNova PLC Ordinary Shares (LIVN)?
What does LivaNova PLC specialize in?
Where is LivaNova PLC headquartered?
On which stock exchange is LivaNova PLC listed?
How many countries does LivaNova operate in?
How many employees does LivaNova PLC have?
What types of products does LivaNova offer?
What significant mergers have shaped LivaNova?
What percentage of LivaNova's revenue comes from the US market?
What recent changes has LivaNova made to its business focus?
How does LivaNova benefit the healthcare industry?
